The growing challenge of obesity and cancer: An inflammatory issue

Annals of the New York Academy of Sciences

Volumn 1229, Issue 1, 2011, Pages 45-52

  Harvey, Alison E ^a   Lashinger, Laura M ^a   Hursting, Stephen D ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Growth factors; Hormones; Inflammation; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GEMCITABINE; GROWTH FACTOR; HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PARTHENOLIDE; PROTEIN INHIBITOR; RAPAMYCIN; RESVERATROL; SIRTUIN INHIBITOR; SOMATOMEDIN C; SULINDAC; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BODY MASS; BREAST CANCER; CALORIC RESTRICTION; CANCER CELL; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL INTERACTION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DIET; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; ENERGY BALANCE; EPITHELIUM CELL; ESOPHAGUS CANCER; EVIDENCE BASED PRACTICE; GENE EXPRESSION; HORMONE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MACROPHAGE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS CANCER; PANCREAS DISEASE; PANCREAS DYSPLASIA; PANCREATITIS; PROTEIN FUNCTION; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 79960820132     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06096.x     Document Type: Article

References (94)

1. Hedley, A.A., C.L. Ogden, C.L. Johnson, et al 2004. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291: 2847-2850.
2. Hossain, P., B. Kawar, & M. El Nahas 2007. Obesity and diabetes in the developing world - a growing challenge. N. Engl. J. Med. 356: 213-215.
3. Calle, E.E., C. Rodriguez, K. Walker-Thurmond & M.J. Thun 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348: 1625-1638.
4. Haffner, S.M. 2006. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity 14(Suppl 3): 121S-127S.
5. Colditz, G.A., W.C. Willett, A. Rotnitzky & J.E. Manson 1995. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Int. Med. 122: 481-486.
6. Wilson, P.W., W.B. Kannel, H. Silbershatz & R.B. D'Agostino 1999. Clustering of metabolic factors and coronary heart disease. Arch. Int. Med. 159: 1104-1109.
7. Kershaw, E.E. & J.S. Flier 2004. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89: 2548-2556.
8. Margetic, S., C. Gazzola, G.G. Pegg & R.A. Hill 2002. Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 26: 1407-1433.
9. Lord, G.M., G. Matarese, J.K. Howard, et al 1998. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394: 897-901.
10. Somasundar, P., D. Riggs, B. Jackson, et al 2003. Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am. J. Surg. 186: 575-578.
11. Yu, H., D. Pardoll & R. Jove 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Rev. 9: 798-809.
12. Houseknecht, K.L., C.A. Baile, R.L. Matteri & M.E. Spurlock 1998. The biology of leptin: a review. J. Anim. Sci. 76.
13. Chang, S., S.D. Hursting, J.H. Contois, et al 2001. Leptin and prostate cancer. Prostate 46: 62-67.
14. Stattin, P., S. Soderberg, G. Hallmans, et al 2001. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J. Clin. Endocrinol. Metab. 86: 1341-1345.
15. Vona-Davis, L. & D.P. Rose 2007. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr.-Relat. Cancer 14: 189-206.
16. Stattin, P., R. Palmqvist, S. Soderberg, et al 2003. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol. Rep. 10: 2015-2021.
17. Stattin, P., A. Lukanova, C. Biessy, et al 2004. Obesity and colon cancer: does leptin provide a link? Int. J. Cancer 109: 149-152.
18. Somasundar, P., A.K. Yu, L. Vona-Davis & D.W. McFadden 2003. Differential effects of leptin on cancer in vitro. J. Surg. Res. 113: 50-55.
19. Jaffe, T. & B. Schwartz 2008. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int. J. Cancer 123: 2543-2556.
20. Havel, P.J. 2002. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 13: 51-59.
21. Byeon, J.-S., J.-Y. Jeong, M.J. Kim, et al 2010. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int. J. Cancer 127: 2758-2767.
22. Rzepka-Gorska, I., R. Bedner, A. Cymbaluk-Ploska & A. Chudecka-Glaz 2008. Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women. Eur. J. Gynaecol. Oncol. 29: 594-597.
23. Tian, Y.F., C.H. Chu, M.H. Wu, et al 2007. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr.-Relat. Cancer 14: 669-677.
24. Wei, E.K., E. Giovannucci, C.S. Fuchs, W.C. Willett & C.S. Mantzoros 2005. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J. Natl. Cancer Inst. 97: 1688-1694.
25. Sher, D.J., W.K. Oh, S. Jacobus, et al 2008. Relationship between serum adiponectin and prostate cancer grade. Prostate 68: 1592-1598.
26. Barb, D. et al Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am. J. Clin. Nutr. 86: 858S-866S.
27. Godsland, I.F. 2010. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin. Sci. 118: 315-332.
28. Kahn, B.B. & J.S. Flier 2000. Obesity and insulin resistance. J. Clin. Invest. 106: 473-481.
29. Pisani, P. 2008. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch. Physiol. Biochem. 114: 63-70.
30. Jazet, I.M., H. Pijl & A.E. Meinders 2003. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth. J. Med. 61: 194-212.
31. Kahn, S.E., R.L. Hull & K.M. Utzschneider 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846.
32. Shoelson, S.E., J. Lee & A.B. Goldfine 2006. Inflammation and insulin resistance. J. Clin. Invest. 116: 1793-1801.
33. Larsson, S.C., L. Bergkvist & A. Wolk 2006. Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. Am. J. Clin. Nutr. 84: 1171-1176.
34. Huxley, R., A. Ansary-Moghaddam, A. Berrington de Gonzalez, et al 2005. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92: 2076-2083.
35. Lindblad, P., W.H. Chow, J. Chan, et al 1999. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42: 107-112.
36. Friberg, E., C.S. Mantzoros, & A. Wolk 2007. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol. Biomarkers Prev. 16: 276-280.
37. Kaaks, R. 1996. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 7: 605-625.
38. Stoll, B.A. 1999. Premalignant breast lesions: role for biological markers in predicting progression to cancer. Eur. J. Cancer 35: 693-697.
39. Renehan, A.G., D.L. Roberts & C. Dive 2008. Obesity and cancer: pathophysiological and biological mechanisms. Arch. Physiol. Biochem. 114: 71-83.
40. LeRoith, D. & C.T. Roberts 2003. The insulin-like growth factor system and cancer. Cancer Lett. 195: 127-137.
41. Calle, E.E. & M.J. Thun 2004. Obesity and cancer. Oncogene 23: 6365-6378.
42. Frystyk, J. 2004. Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 14: 337-375.
43. Wolk, A., C.S. Mantzoros, S.O. Andersson, et al 1998. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 90: 911-915.
44. Cutting, C.W., C. Hunt, J.A. Nisbet, et al 1999. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int. 83: 996-999.
45. Hankinson, S.E., W.C. Willett, G.A. Colditz, et al 1998. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396.
46. Ma, J., M.N. Pollak, E. Giovannucci, et al 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91: 620-625.
47. Saxena, N.K., L. Taliaferro-Smith, B.B. Knight, et al 2008. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 68: 9712-9722.
48. Olivo-Marston, S.E., S.D. Hursting, J. Lavigne, et al 2009. Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol. Carcinog. 48: 1071-1076.
49. Hursting, S.D., S.M. Smith, L.M. Lashinger 2010. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis 31: 83-89.
50. Bhattacharya, A., B. Chandrasekar, M.M. Rahman, et al 2006. Inhibition of inflammatory response in transgenic fat-1 mice on a calorie-restricted diet. Biochem. Biophys. Res. Commun. 349: 925-930.
51. Charriere, G., B. Cousin, E. Arnaud, et al 2003. Preadipocyte conversion to macrophage. Evidence of plasticity. J. Biol. Chem. 278: 9850-9855.
52. O'Rourke, R.W. 2009. Inflammation in obesity-related diseases. Surgery 145: 255-259.
53. Carey, D.G., G.J. Cowin, G.J. Galloway, et al 2002. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes. Res. 10: 1008-1015.
54. Subbaramaiah, K., L.R. Howe, P. Bhardwaj, et al 2011. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res. 4: 329-346.
55. Kim, T., S. Choi, E. Ha, et al 2011. IL-6 induction of TLR-4 gene expression via STAT3 has an effect on insulin resistance in human skeletal muscle. Acta Diabetologica 1-12.
56. Fontana, L., J.C. Eagon, M.E. Trujillo, et al 2007. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56: 1010-1013.
57. Fenton, J.I., S.D. Hursting, S.N. Perkins & N.G. Hord 2006. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line. Carcinogenesis 27: 1507-1515.
58. Dolcet, X., D. Llobet, J. Pallares & X. Matias-Guiu 2005. NF-kB in development and progression of human cancer. Virchows Arch. 446: 475-482.
59. Rouet-Benzineb, P., T. Aparicio, S. Guilmeau, et al 2004. Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. J. Biol. Chem. 279: 16495-16502.
60. Kim, D.H., J.Y. Kim, B.P. Yu & H.Y. Chung 2008. The activation of NF-kappaB through Akt-induced FOXO1 phosphorylation during aging and its modulation by calorie restriction. Biogerontology 9: 33-47.
61. Mitsiades, C.S., N. Mitsiades, V. Poulaki, et al 2002. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21: 5673-5683.
62. Balkwill, F. & A. Mantovani 2001. Lancet. 357: 539-545.
63. Foltz, C.J., J.G. Fox, R. Cahill, et al 1998. Helicobacter. 3: 69-78.
64. Coussens, L.M. & Z. Werb 2002. Inflammation and cancer. Nature 420: 860-867.
65. Balkwill, F., K.A. Charles & A. Mantovani 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 7: 211-217.
66. Karin, M. 2005. Inflammation and cancer: the long reach of Ras. Nature Med. 11: 20-21.
67. Karin, M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
68. Ishigami, S., S. Natsugoe, K. Tokuda, et al 2000. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88: 577-583.
69. Ribatti, D., M.G. Ennas, A. Vacca, et al 2003. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest. 33: 420-425.
70. Leek, R.D., R.J. Landers, A.L. Harris & C.E. Lewis 1999. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79: 991-995.
71. Koki, A., N.K. Khan, B.M. Woerner, et al 2002. Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 507: 177-184.
72. Tlsty, T.D. & L.M. Coussens 2006. Tumor stroma and regulation of cancer development. Ann. Rev. Pathol. 1: 119-150.
73. Lin, W.W. & M. Karin 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117: 1175-1183.
74. Hosokawa, T., K. Kusugami, K. Ina, et al 1999. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J. Gastroenterol. Hepatol. 14: 987-996.
75. Allavena, P., A. Sica, C. Garlanda & A. Mantovani 2008. The yin-yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222: 155-161.
76. Mantovani, A., S. Sozzani, M. Locati, et al 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555.
77. Greten, F.R., L. Eckmann, T.F. Greten, et al 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296.
78. Pikarsky, E., R.M. Porat, I. Stein, et al 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466.
79. Stark, L.A., F.V. Din, R.M. Zwacka & M.G. Dunlop 2001. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 15: 1273-1275.
80. Colby, J.K., R.D. Klein, M.J. McArthur, et al 2008. Neoplasia, N.Y. 10: 782-796.
81. El-Rayes, B.F., S. Ali, F.H. Sarkar & P.A. Philip 2004. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 3: 1421-1426.
82. Cascinu, S., R. Berardi, R. Labianca, et al 2008. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 9: 39-44.
83. Yamamoto, Y., M.J. Yin, K.M. Lin & R.B. Gaynor 1999. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274: 27307-27314.
84. Yip-Schneider, M.T., H. Nakshatri, C.J. Sweeney, et al 2005. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol. Cancer Ther. 4: 587-594.
85. Ma, M.H., H.H. Yang, K. Parker, et al 2003. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9: 1136-1144.
86. Shishodia, S., H.M. Amin, R. Lai & B.B. Aggarwal 2005. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 70: 700-713.
87. Weisberg, S.P., R. Leibel & D.V. Tortoriello 2008. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149: 3549-3558.
88. Chen, H., Z.S. Zhang, Y.L. Zhang & D.Y. Zhou 1999. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res. 19: 3675-3680.
89. Li, L., B.B. Aggarwal, S. Shishodia, et al 2004. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101: 2351-2362.
90. Limtrakul, P., S. Lipigorngoson, O. Namwong, et al 1997. Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett. 116: 197-203.
91. Huang, M.T., H.L. Newmark & K. Frenkel 1997. Inhibitory effects of curcumin on tumorigenesis in mice. Journal of cellular biochemistry. J. Cell. Biochem. 27: 26-34.
92. Chuang, S.E., A.L. Cheng, J.K. Lin & M.L. Kuo 2000. Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem. Toxicol. 38: 991-995.
93. Singh, S. & B.B. Aggarwal 1995. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem. 270: 24995-25000.
94. Pandelidou, M., K. Dimas, A. Georgopoulos, et al 2011. Preparation and characterization of lyophilised EGG PC liposomes incorporating curcumin and evaluation of its activity against colorectal cancer cell lines. J. Nanosci. Nanotechnol. 11: 1259-1266.